We are live on !
Find out more
Sphera Funds Management Portfolio holdings
AUM
$767M
Turnover
36.59%
1-Year Est. Return
119.71%
This Fund
S&P 500
This Quarter Est. Return
+18.13%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$767M
AUM Growth
+$137M
(+22%)
Cap. Flow
+$31.2M
Cap. Flow % of AUM
Cap. Flow %
4.08%
Top 10 Holdings %
Top 10 Hldgs %
34.48%
Holding
123
New
27
Increased
33
Reduced
30
Closed
18
Avg Time Held
Equity + Options
1.4
years
Top 10 Avg Time Held
Equity + Options
0.5
years
Top 20 Avg Time Held
Equity + Options
1.4
years
Avg Time Held Equity only
1.5
years
Top 10 Avg Time Held Equity only
0.6
years
Top 20 Avg Time Held Equity only
1.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Insmed
INSM
|
+$14.4M |
| 2 |
Cytokinetics
CYTK
|
+$12.9M |
| 3 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$12.1M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$10.3M |
| 5 |
Rhythm Pharmaceuticals
RYTM
|
+$7.27M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nova
NVMI
|
+$14.5M |
| 2 |
Tower Semiconductor
TSEM
|
+$8.98M |
| 3 |
Amicus Therapeutics
FOLD
|
+$8.72M |
| 4 |
Cellebrite
CLBT
|
+$8.7M |
| 5 |
Apellis Pharmaceuticals
APLS
|
+$8.65M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 80.09% |
| 2 | Miscellaneous | 10.43% |
| 3 | Technology | 7.55% |
| 4 | Utilities | 1.93% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Teva Pharmaceutical Industries Limited
TEVA
$48.3B
| $50.8M | 6.63% |
1,500,082
+363,107
| +32% | +$12.1M |
2023 Q1
13 quarters
|
|
2
Mineralys Therapeutics
MLYS
$1.82B
| $39.7M | 5.17% |
1,469,971
+130,000
| +10% | +$3.57M |
2023 Q1
13 quarters
|
|
|
3
Tower Semiconductor
TSEM
$22.6B
| $28.2M | 3.68% |
108,265
-37,470
| -26% | -$8.98M |
2023 Q2
12 quarters
|
|
4
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.2B
| $23.7M | 3.1% |
150,000
-50,000
| -25% | -$6.76M |
2025 Q4
2 quarters
|
|
5
Syndax Pharmaceuticals
SNDX
$1.16B
| $22.2M | 2.89% |
1,014,606
+290,043
| +40% | +$6.03M |
2020 Q1
25 quarters
|
|
6
CALL
Biogen
BIIB
$34.8B
| $21.6M | 2.82% |
+100,000
| New | +$19.1M |
2026 Q2
0 quarters
|
|
|
7
Biogen
BIIB
$34.8B
| $20.9M | 2.72% |
96,626
+4,100
| +4% | +$784K |
2022 Q3
15 quarters
|
|
8
Ultragenyx Pharmaceutical
RARE
$1.48B
| $19.6M | 2.56% |
588,494
-220,839
| -27% | -$5.49M |
2022 Q3
15 quarters
|
|
|
9
BioMarin Pharmaceuticals
BMRN
$10.6B
| $18.8M | 2.45% |
328,550
+188,650
| +135% | +$10.3M |
2025 Q4
2 quarters
|
|
|
10
Cytokinetics
CYTK
$8.76B
| $18.7M | 2.44% |
219,987
+180,170
| +452% | +$12.9M |
2023 Q3
11 quarters
|
|
11
BridgeBio Pharma
BBIO
$13.3B
| $18.3M | 2.38% |
245,346
+100
| +0% | +$7K |
2023 Q1
13 quarters
|
|
12
Cogent Biosciences
COGT
$5.21B
| $17.8M | 2.32% |
459,340
+43,000
| +10% | +$1.5M |
2025 Q1
5 quarters
|
|
|
13
Nova
NVMI
$10.2B
| $13.7M | 1.78% |
25,169
-28,197
| -53% | -$14.5M |
2024 Q3
7 quarters
|
|
|
14
Insmed
INSM
$20.9B
| $12.7M | 1.65% |
+118,800
| New | +$14.4M |
2026 Q2
0 quarters
|
|
15
Maze Therapeutics
MAZE
$1.68B
| $12.5M | 1.63% |
417,564
+190,221
| +84% | +$4.99M |
2025 Q1
5 quarters
|
|
16
AstraZeneca
AZN
$256B
| $11.9M | 1.55% |
62,530
| – | – |
2020 Q1
25 quarters
|
|
17
Sanofi
SNY
$95.3B
| $11.5M | 1.5% |
269,515
| – | – |
2021 Q1
21 quarters
|
|
|
HELP
18
Helus Pharma Inc. Common Stock
HELP
$775M
| $10.7M | 1.4% |
1,620,753
+633,663
| +64% | +$3.17M |
2024 Q1
9 quarters
|
|
19
Eli Lilly
LLY
$1.12T
| $9.6M | 1.26% |
8,040
-1,000
| -11% | -$1.02M |
2020 Q2
24 quarters
|
|
20
Madrigal Pharmaceuticals
MDGL
$10.3B
| $9.35M | 1.22% |
17,419
+8,379
| +93% | +$4.29M |
2025 Q4
2 quarters
|
|
21
Trevi Therapeutics
TRVI
$1.69B
| $9.31M | 1.21% |
499,029
-75,000
| -13% | -$1.09M |
2025 Q2
4 quarters
|
|
22
Acadia Pharmaceuticals
ACAD
$3.38B
| $9.02M | 1.18% |
356,534
+100,332
| +39% | +$2.21M |
2025 Q2
4 quarters
|
|
23
Celldex Therapeutics
CLDX
$2.31B
| $8.96M | 1.17% |
240,868
-2,707
| -1% | -$87.4K |
2023 Q2
12 quarters
|
|
|
24
Rhythm Pharmaceuticals
RYTM
$6.06B
| $8.93M | 1.16% |
+80,400
| New | +$7.27M |
2026 Q2
0 quarters
|
|
|
25
CALL
Cytokinetics
CYTK
$8.76B
| $8.52M | 1.11% |
100,000
-159,300
| -61% | -$11.4M |
2026 Q1
1 quarter
|
|
Similar funds
Sphera Funds Management's Q2 2026 Portfolio in Review
As of Q2 2026, Sphera Funds Management held 123 positions worth $767M, up 22% from $630M the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Sphera Funds Management deployed $31.2M of net new capital in Q2 2026, opening 27 new positions and adding to 33 existing holdings. Its largest new stake was Insmed: 118,800 shares worth $12.7M.
By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 74% a quarter earlier, followed by Miscellaneous and Technology.
On the sell side, the largest reduction was Nova, an estimated $14.5M trimmed.
- Sphera Funds Management's largest Q2 2026 buy was Insmed: 118,800 shares worth $12.7M.
- Sphera Funds Management added most to Cytokinetics in Q2 2026, an estimated $12.9M increase.
- Sphera Funds Management's biggest Q2 2026 reduction was Nova, cutting an estimated $14.5M.
- Sphera Funds Management fully exited Amicus Therapeutics in Q2 2026, selling an estimated $8.72M.
- Sphera Funds Management's ten largest holdings make up 34% of its $767M portfolio in Q2 2026.
- Sphera Funds Management opened 27 new positions and closed 18 in Q2 2026.
- Sphera Funds Management's portfolio value rose 22% quarter-over-quarter to $767M.
Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.